Chiara Battelli, MD
Hematology & Oncology · Westbrook, MENPI 1831398551
Payments from drug & device makers
Across 456 payments — averaging $3207.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$431K
- E.r. Squibb & Sons, L.L.C.$262K
- Pfizer$256K
- Genentech, Inc.$198K
- Eli Lilly$119K
- AstraZeneca$53K
- plus $143K from 22 others
Across 4 payments — averaging $1393.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6K
What the payments were for
- Food & beverage$90698%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 46 | $431,330 |
| E.r. Squibb & Sons, L.L.C. | 8 | $262,412 |
| Pfizer | 298 | $256,214 |
| Genentech, Inc. | 31 | $197,527 |
| Eli Lilly | 13 | $118,743 |
| AstraZeneca | 4 | $53,368 |
| Daiichi Sankyo Inc. | 15 | $38,745 |
| Astrazeneca UK Limited | 1 | $31,250 |
| Sanofi US Services Inc. | 2 | $27,235 |
| G1 Therapeutics, Inc. | 8 | $23,000 |
| Macrogenics, Inc. | 3 | $21,687 |
| Biontech SE | 2 | $184 |
| AbbVie | 5 | $153 |
| Elekta, Inc. | 2 | $128 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $125 |
| Varian Medical Systems, Inc. | 1 | $71 |
| ASD Specialty Healthcare, LLC | 1 | $70 |
| GSK | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Amgen | 1 | $11 |
| Exelixis Inc. | 1 | $11 |
How this compares
$1,462,435 in reported general payments places this provider in the 95th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 126 | $1,720,431 |
| IbrancePalbociclib | 23 | $289,276 |
| XareltoRivaroxaban | 17 | $25,711 |
| Exemestane | 96 | $15,906 |
| EliquisApixaban | 22 | $12,669 |
| Letrozole | 360 | $8,803 |
| EligardLeuprolide Acetate | 13 | $5,579 |
| Anastrozole | 225 | $4,916 |
| Tamoxifen Citrate | 162 | $3,950 |
| Duloxetine Hcl | 29 | $891 |
| Potassium Chloride | 13 | $309 |
| Alendronate Sodium | 57 | $254 |
| Ondansetron OdtOndansetron | 14 | $197 |
| Gabapentin | 17 | $136 |
| Escitalopram Oxalate | 18 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $256,214 | $301,94545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Westbrook
- Christian ThomasWestbrook$4.7M
- Matthew DuganWestbrook$675K
- John WintersWestbrook$341K
- Devon EvansWestbrook$248K
- Eleni NackosWestbrook$217K
- Tracey WeisbergWestbrook$109K
- Daniel RauschWestbrook$104K
- Patrick BolandWestbrook$20K
- Owen PickusWestbrook$1K
- Anna NiegowskaPortland$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.